Showing 1 - 4 results of 4 for search 'M. Fleischmann', query time: 0.25s Refine Results
  1. 1
    Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

    Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®)... by Roy M. Fleischmann, Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke Alten

    Published 2021-09-01
    Get full text
    Article
  2. 2
    A systematic review of inclusive pedagogical research using the CIRTL inclusive pedagogy framework: multi-disciplinary and STEM perspectives, current trends and a research agenda

    A systematic review of inclusive pedagogical research using the CIRTL inclusive pedagogy framework: multi-disciplinary and STEM perspectives, current trends and a research agenda by Angela G. Jackson-Summers, Karina L. Mrakovcich, Joshua P. Gray, Corinna M. Fleischmann, Tooran Emami, Eric J. Page

    Published 2024-03-01
    Get full text
    Article
  3. 3
    The role of loneliness in the development of depressive symptoms among partnered dementia caregivers: Evidence from the English Longitudinal Study of Aging

    The role of loneliness in the development of depressive symptoms among partnered dementia caregivers: Evidence from the English Longitudinal Study of Aging by J. P. Saadi, E. Carr, M. Fleischmann, E. Murray, J. Head, A. Steptoe, R. A. Hackett, B. Xue, D. Cadar

    Published 2021-01-01
    Get full text
    Article
  4. 4
    A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

    A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis by Roy M. Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y. Hua, Carol Cronenberger, Daniel Alvarez, Amy E. Bock, K. Lea Sewell

    Published 2018-08-01
    Get full text
    Article

Search Tools: